Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Increasing cardiac troponin-I level as a cardiac injury index correlates with in-hospital mortality and biofactors in severe hospitalised COVID-19 patients

Reza Javidi Dasht Bayaz, Vahid Reza Askari, Mohammad Tayyebi, Mostafa Ahmadi, Alireza Heidari-Bakavoli, Vafa Baradaran Rahimi

1. Introduction

Coronavirus disease 2019 (COVID-19) is a recently recognised and serious infectious disease that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has spread quickly throughout almost every country around the world and has become a global pandemic [1]. The most common symptoms are fever, cough, fatigue, gastrointestinal complaints such as diarrhoea and nausea, lymphopenia, and stimulated levels of inflammatory cytokines [2,3]. The involvement of the nervous system has also been noticed, manifesting as headache, dizziness, and altered conscious state [4]. In addition, up to 15% of patients with COVID-19 experienced the severe form of interstitial pneumonia that may lead to acute respiratory distress syndrome (ARDS), decreased oxygen saturation, multi-organ failure, and death [5].

ARTICLE INFO

** Keywords: **COVID-19 Cardiac injury Troponin I Mortality D-dimer

ABSTRACT

** Background: **Severe acute respiratory syndrome coronavirus-2 raised in 2019 (COVID-19) affects the lung tissue and other organs, specifically the heart.

** Methods: **The current study evaluated 120 hospitalised patients with severe COVID-19 between March 2021 and February 2022. Patients' demographics, vital signs, electrocardiogram abnormalities, clinical laboratory tests, including troponin I (TPI), mortality, and discharge type, were recorded.

** Results: **Among the 120 hospitalised patients with severe COVID-19, 54 (45.0%) patients were male, with an average age of 63.2 ± 1.4. Many patients have chronic comorbidities, including hypertension (51.6%), diabetes mellitus (34.1%), and ischemic heart disease (17.5%). The in-hospital and six months after the discharge mortality were 45.8% and 21.5%, respectively. Cardiac injury was observed in 14 (11.7%) patients with a mean TPI level of 8.386 ± 17.89 μg/L, and patients with cardiac injury had higher mortality than those without cardiac injury (P < 0.001). Furthermore, the cardiac injury was meaningfully correlated with age (ρ = 0.182, P = 0.019), history of ischemic heart disease (ρ = 0.176, P = 0.05), hospitalisation result and mortality (ρ = 0.261, P = 0.004), inpatient in ICU (ρ = 0.219, P = 0.016), and serum levels of urea (ρ = 0.244, P = 0.008) and creatinine (ρ = 0.197, P = 0.033). Additionally, the discharge results were significantly correlated with oxygen saturation with (ρ = -0.23, P = 0.02) and without (ρ = -0.3, P = 0.001) oxygen therapy, D-dimer (ρ = 0.328, P = 0.019), LDH (ρ = 0.308, P = 0.003), urea (ρ = 0.2, P = 0.03), and creatinine (ρ = 0.17, P = 0.06) levels.

** Conclusion: **Elevated TPI levels are associated with increased mortality in severe COVID-19 patients. Therefore, TPI may be a beneficial biofactor for early diagnosis of cardiac injury and preventing a high mortality rate.
Several pieces of evidence emphasised that cardiac troponin-I (TPI) elevation is associated with worse mortality in both cardiovascular and non-cardiovascular disorders [6,7]. Moreover, previous recent studies reported that patients with COVID-19 may experience major cardiac complications, including acute cardiac injury and myocardial infarction, which are characterised by elevated TPI levels. Additionally, this was associated with worsening severe prognosis and a higher risk of in-hospital mortality in these patients [8,9]. Therefore, the present study aimed to determine the clinical findings, the prevalence of cardiac injury, in-hospital mortality, and six months after discharge mortality in hospitalised patients with severe COVID-19 and evaluate the possible relationship between these factors.

2. Patients and methods

2.1. Ethical statements

This study was ethically approved by the ethics committee of Mashhad University of Medical Sciences (approval code. IR.MUMS. MEDICAL.REC.1399.579). Furthermore, written informed consent was obtained and signed by all participants.

2.2. Study design

This prospective clinical study was conducted on 120 hospitalised patients with severe COVID-19 referred to the Imam Reza Hospital affiliated with Mashhad University of Medical Sciences, Mashhad, Khorasan Razavi province, Iran, from March 2021 to February 2022. In addition, patients were included with COVID-19’s positive polymerase chain reaction (PCR) test, hospitalised in the COVID-19 ward of Imam Reza Hospital, aged between 18 and 70 years, and had a written signed consent to participate in the present study. A severe type of COVID-19 was diagnosed in hospitalised patients with COVID-19 who had at least one of the following criteria: (1) dyspnea, respiratory frequency ≥30/minute, (2) blood oxygen saturation ≤93% at rest, (3) respiratory failure with requiring mechanical ventilation, (4) transferred to the intensive care unit (ICU), or (5) death [10].

2.3. Definition of cardiac injury

The cardiac injury diagnosis was made using the TPI level in the enrolled patients in the first 24 h of admission. The TPI levels less than 0.6 μg/L were considered no cardiac injury, and TPI levels more than 0.6 μg/L were recorded as confirmed cardiac injury according to the commercially available TPI kit ranges.

2.4. Evaluation of outcomes

Patient’s demographic information, including age, gender, underlying diseases, and medication history, were recorded. Moreover, the clinical laboratory tests were conducted within 24 h after admission, including troponin I (TPI), lactate dehydrogenase (LDH), D-dimer, creatinine (Cr), and white blood cells (WBC) and absolute lymphocytes count (ALC). Vital signs were also documented, including blood pressure (BP), respiratory rate (RR), pulse rate (PR), and blood oxygen saturation with and without oxygen therapy. In addition, electrocardiogram abnormalities were obtained, and the individual cardiology specialist performed all electrocardiography and their interpretation.

The discharge results were categorised in one of the following four statuses: (1) discharge with good health condition, (2) discharge with complications such as decreased respiratory capacity, (3) death, and (4) discharge against medical advice (DAMA). Furthermore, the final health status of the patients was also checked six months after discharge. It was represented as (1) good health status, with no re-hospitalisation, (2) good health status, with re-hospitalisation, (3) death, and (4) no access (patients were unreachable due to not answering their phones and our calling). In-hospital mortality and mortality within six months after discharge were observed.

2.5. Statistical analysis

Data were analysed using the SPSS version 22 statistical software (SPSS Inc., Chicago, Illinois) and expressed according to the nature of parametric and non-parametric as means ± SD or number with percentage, respectively. The comparison between two continuous variables was performed using Student’s t-test. Finally, the comparison between categorical variables was made using the Chi-square test. As appropriate, the correlation between results was evaluated using Pearson or Spearman test. The levels of P values (P) ≤ 0.05, 0.01, and 0.001 were considered statistically significant.

3. Results

3.1. Demographic information

As illustrated in Table 1, Among the 120 hospitalised patients with severe COVID-19, 54 (45.0%) patients were male, and 66 (55.0%) patients were female, with an average age of 63.2 ± 1.4 years. Many patients had chronic comorbidities, including hypertension (62, 51.6%), diabetes mellitus (41, 34.1%), and ischemic heart disease (21, 17.5%). Additionally, the prior medications are presented in Table 1, in which 51 (42.5%) patients took anti-hypertensive drugs, 24 (20.0%) took aspirin, 29 (24.2%) patients received tylosalicylic acid (ASA), and 17 (14.16%) patients were smokers.

3.2. Prescribed medications, hospitalisation and follow-up results

During the hospitalisation period, 29 (24.2%) patients received famotidine, 5 (4.2%) patients received hydroxychloroquine, and 96 (80%) patients received remdesivir. As a result, the total days of hospital stay were 18.8 ± 19.19 days, ranging from 2 to 144 days, and 88 (73.3%) patients needed to be admitted to the ICU (Table 1). Among the total 120 hospitalised patients, 53 (44.2%), 2 (1.7%), 10 (8.3%) patients were discharged in good general condition, with compliance, and against medical advice, respectively, and 55 (45.8%) patients were dead. Furthermore, the results of six months of follow-up after discharge showed that 35 (53.8%) patients had good health status with no re-hospitalisation, 2 (3.7%) patients had good health status with re-hospitalisation, and 14 (21.5%) patients had died. Unfortunately, we could not access the remaining 14 (21.5%) patients (Table 1).

### Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ALC | absolute lymphocytes count |
| BP | blood pressure |
| BUN | blood urea nitrogen |
| COVID-19 | Coronavirus disease 2019 |
| Cr | creatinine |
| DAMA | Discharge against medical advice |
| ICU | intensive care unit |
| LDH | lactate dehydrogenase |
| PR | pulse rate |
| RR | respiratory rate |
| SARS-CoV-2 | severe acute respiratory syndrome coronavirus 2 |
| TPI | troponin I |
Table 1
Demographic characteristics, prescribed medications, hospitalisation and follow-up, and electrocardiogram abnormalities results of patients enrolled on the study.

| Characteristics | Mean ± SD or N (%) |
|-----------------|--------------------|
| Comorbidities   |                    |
| Age (Years)     | 63.2 ± 1.4         |
| Gender          | Male 54 (45.0%)    |
|                 | Female 66 (55.0%)  |
| Pertension      | 62 (51.6%)         |
| Diabetes mellitus | 41 (34.1%)  |
| Ischemic heart disease | 21 (17.5%) |
| Prior medication |                    |
| Drugs           |                    |
| Famotidine      | Yes 29 (24.2%)     |
|                 | No 91 (75.8%)      |
| Hydroy          | Yes 5 (4.2%)       |
|                 | No 115 (95.8%)     |
| Chloroquine     | Yes 96 (80%)       |
|                 | No 20 (104%)       |
| Remdeseric      | Yes 88 (73.3%)     |
|                 | No 32 (26.7%)      |
| Hospitalisation result |            |
| Death           | Yes 14 (11.7%)     |
|                 | No 106 (88.3%)     |
| Follow-up 6-months after discharge |                |
| Death           | Yes 14 (11.7%)     |
|                 | No 106 (88.3%)     |
| P Abnormality    |                    |
| Symptomatic tachycardia | 16 (13.2%) |
| PSVT            | 1 (0.8%)           |
| LV enlargement   | 1 (0.8%)           |
| AF with rapid ventricular rhythm | 1 (0.8%) |
| No              | 100 (83.3%)        |
| PR Abnormality   |                    |
| Long PR         | 1 (0.8)            |
| Short PR        | 2 (1.6)            |
| No              | 117 (97.5)         |
| QRS Abnormality  |                    |
| LAD             | 21 (16.15%)        |
| RAD             | 2 (1.53%)          |
| LBBB            | 3 (2.3%)           |
| RBBB            | 1 (0.76%)          |
| PAC             | 3 (2.4%)           |
| PVC             | 2 (2.3%)           |
| Poor R progression | 10 (7.7%)         |
| Low voltage     | 3 (2.4%)           |
| None            | 85 (65.38%)        |
| ST Abnormality   |                    |
| ST depression    | 5 (4.23%)          |
| T inverse        | 5 (4.23%)          |
| Prexitation in ST segment | 1 (0.84%) |
| None            | 107 (90.67%)       |
| QT Abnormality   |                    |
| Long QT         | 6 (4.8%)           |
| None            | 114 (91.2%)        |

ICU: Intensive care unit, PSVT: Paroxysmal supraventricular tachycardia, LV: Left ventricular, AF: Atrial fibrillation, LAD: Left axis deviation, RAD: Right axis deviation, LBBB: Left bundle branch block, RBBB: Right bundle branch block, PAC: Premature atrial contractions, PVC: Premature ventricular contractions.

3.3. Cardiac injury findings

Our results revealed that 106 (88.3%) patients experienced no cardiac injury with a mean TPI level of 0.1555 ± 0.091 μg/L. In addition, confirmed cardiac injury was observed in 14 (11.7%) patients with a mean TPI level of 8.386 ± 17.89 μg/L ranging from 0.71 μg/L to 66.8 μg/L (Table 2).

3.4. Vital signs and clinical laboratory tests

The vital signs of patients, including systolic BP, diastolic BP, PR, RR, body temperature, and oxygen saturation with and without oxygen therapy, are illustrated in Table 2. We observed that 102 (85%) patients had oxygen saturation below 93% at admission, with a mean of 79.9 ± 13.8%, ranging from 36% to 99%. After oxygen therapy, 56 (46.6%) patients had oxygen saturation below 93%, with a mean of 89.7 ± 7.9%, ranging from 56% to 99%.

The results of clinical laboratory tests of patients at admission, including TPI, CRP, D-dimer, LDH, urea, Cr, WBC, and ALC, are presented in Table 2. We observed that 102 (85%) patients had oxygen saturation below 93% at admission, with a mean of 79.9 ± 13.8%, ranging from 36% to 99%. After oxygen therapy, 56 (46.6%) patients had oxygen saturation below 93%, with a mean of 89.7 ± 7.9%, ranging from 56% to 99%.

The results of clinical laboratory tests of patients at admission, including TPI, CRP, D-dimer, LDH, urea, Cr, WBC, and ALC, are presented in Table 2. The mean total TPI level was 1.08 ± 0.06 μg/L ranging from 0.01 μg/L to 66.8 μg/L. In addition, the mean TPI level in the death group and discharged in good general condition was 0.07 ± 0.06 μg/L and 2.27 ± 9.58 μg/L, respectively.

Table 2
Vital signs and clinical laboratory tests of patients at the time of admission.

| Characteristics | Mean ± SD | Min | Max |
|-----------------|-----------|-----|-----|
| Vital signs     |           |     |     |
| Systolic BP (mmHg) | 126.9 ± 21.58 | 70  | 200 |
| Diastolic BP (mmHg) | 77.6 ± 12.7 | 50  | 114 |
| PR (beats per minute) | 95.3 ± 7.6 | 57  | 152 |
| O2 saturation with oxygen therapy (%) | 89.7 ± 7.9 | 56  | 99 |
| O2 saturation without oxygen therapy (%) | 79.9 ± 13.8 | 36  | 99 |
| Temperature (°C) | 37.5 ± 0.79 | 36  | 40 |
| RR (breaths per minute) | 21.4 ± 8.4 | 12  | 93 |
| TPI (μg/L)      | 1.08 ± 6.54 | 0.01 | 66.8 |
| CRP (μg/mL)     | 94.0 ± 1.3 | 1.3 | 244.7 |
| D-dimer (μg/mL) | 2503.2 ± 55.19 | 130 | 1000 |
| LDH (U/L)       | 487.0 ± 2767.6 | 263 | 4067 |
| Urea (mg/dL)    | 62.6 ± 25.07 | 12  | 359 |
| Cr (mg/dL)      | 1.37 ± 1.21 | 0.5 | 359 |
| Na (mEq/dL)     | 136.6 ± 6.06 | 123 | 159 |
| K (mEq/dL)      | 4.01 ± 0.75 | 1.2 | 6.5 |
| Hg (g/dL)       | 12.38 ± 7.3 | 14.8 | 18.4 |
| WBC (million/μL) | 14.63 ± 21.7 | 2.1 | 167.6 |
| ALC (million/μL) | 1699.38 ± 22.17 | 72.0 | 26192.0 |
| GFR (mL/min/1.73 m²) | 63.5 ± 3140.8 | 5.5 | 159 |

BP: Blood pressure, PR: Pulse rate, RR: Respiratory rate, TPI: Troponin I, CRP: C-reactive protein, LDH: Lactate dehydrogenase, Cr: Creatinine, Na: Sodium, K: Potassium, Hg: Hemoglobin, WBC: White blood cell, ALC: Absolute lymphocytes count, GFR: Glomerular filtration rate.
3.5. Findings of electrocardiogram abnormalities

Different electrocardiogram abnormalities, including P, PR, QRS, ST, and QT abnormalities, are described in Table 1. Our results figured out that 20 (16.6%) cases of P abnormality, 3 (2.5%) cases of PR abnormality, 45 (34.62%) cases of QRS abnormality, 11 (9.33%) cases of ST abnormality, and 6 (4.8%) cases of QT abnormality were observed in the electrocardiogram of the patients with COVID-19.

3.6. Demographics and clinical characteristics of patients with and without cardiac injury

The values of different measured variables according to and without cardiac injury are presented in Table 3. The mean age (P = 0.04) and levels of LDH (0.005), urea (P < 0.001), and Cr (P < 0.001) were significantly higher in patients with cardiac injury than those with no cardiac injury group. In contrast, the oxygen saturation with oxygen therapy was notably lower in patients with cardiac injury than in those with no cardiac injury group. In contrast, the oxygen saturation with oxygen therapy was significantly higher in patients with cardiac injury than in those with no cardiac injury group. The oxygen saturation without oxygen therapy was notably lower in patients with cardiac injury than in those with no cardiac injury group (P = 0.017). In addition, the inpatient in ICU (P = 0.016), death (P < 0.001), and discharge in good condition (P < 0.001) were significantly different between the two groups. Patients with a cardiac injury had higher mortality than those without cardiac injury [14 of 14 (100%) vs 41 of 106 (38.7%), P < 0.001]. Although the GFR levels were lower in the cardiac injury group, no statistically significant differences were found in the GFR levels between the two studied groups (P = 0.076, Table 3).

Table 4 illustrates the correlation between cardiac injury and different measured parameters. We found that cardiac injury was meaningfully correlated with age (P = 0.182, P = 0.019), history of ischemic heart disease (P = 0.176, P = 0.05), hospitalisation result (P = 0.261, P = 0.004), inpatient in ICU (P = 0.219, P = 0.016), and serum levels of urea (P = 0.244, P = 0.008) and Cr (P = 0.197, P = 0.033).

Furthermore, the correlation between hospitalisation results and different measured parameters is represented in Table 5. Our results revealed that the discharge result significantly correlated with hydroxy chloroquine use (P = 0.22, P = 0.014), oxygen saturation with oxygen therapy (P = 0.23, P = 0.02), oxygen saturation without oxygen therapy (P = 0.3, P = 0.03), and Cr (P = 0.17, P = 0.06).

4. Discussion

This prospective clinical study evaluated data from 120 hospitalised patients with COVID-19. We revealed that the mortality rate of patients during the hospitalisation period and six months after discharge was 45.8% and 21.5%, respectively. Furthermore, cardiac injury was observed in 11.7% of patients with a mean TPI level of 8.386 ± 17.89 μg/L. In-hospital death patients had higher levels of TPI than discharged patients.

We found that 55% of the enrolled patients were female, with an average age of 63.2 ± 1.4 years, and 85.8% were a non-smoker. Many of them had chronic comorbidities, including hypertension, diabetes mellitus, and ischemic heart disease. These results were consistent with previous researchers [11,12]. In addition, the total hospital stay was 18.8 ± 19.19 days, and 73.3% were inpatients in ICU. Similarly, Li et al. reported that the total hospital stay was 21.0 [interquartile range (IQR) 15.0–39.5] in patients with COVID-19 [13].

Our results showed that the prevalence of cardiac damage was 11.7%, and the mortality of COVID-19 was 45.8% in hospitalised patients with severe COVID-19. Previous studies reported the rate of cardiac injury and mortality in COVID-19 patients. Contextually, Lu and coworkers determined that 9.45% of the patients with COVID-19 experienced cardiac injury, and the mortality was 29.6% [14]. Moreover, Fan et al. reported that the prevalence of cardiac injury was 16.44%, and the mortality rate of 64.4% among 73 patients with COVID-19.

Table 3

| Variable                          | Cardiac injury (N = 14) | No cardiac injury (N = 106) | P-value |
|----------------------------------|-------------------------|----------------------------|---------|
| Age (Mean ± SD, years)           | 71.8 ± 15.22            | 62.09 ± 16.22              | 0.04b   |
| Gender (n, %)                    | Male 6 (11.11%)         | 48 (88.8%)                 | 0.55b   |
|                                  | Female 8 (12.12%)       | 58 (87.87%)                |         |
| Hypertension (n, %)              | Yes 7 (11.3%)           | 55 (88.7%)                 | 0.89b   |
|                                  | No 7 (12.06%)           | 51 (87.9%)                 |         |
| Diabetes mellitus (n, %)         | Yes 7 (17.00%)          | 34 (82.9%)                 | 0.184a  |
|                                  | No 7 (8.8%)             | 72 (91.2%)                 |         |
| Ischemic heart disease (n, %)    | Yes 4 (19.1%)           | 17 (80.9%)                 | 0.25b   |
|                                  | No 10 (10.1%)           | 89 (89.9%)                 |         |
| Remdesivir (n, %)                | Yes 5 (17.24%)          | 24 (82.7%)                 | 0.283c  |
|                                  | No 9 (9.9%)             | 82 (90.1%)                 |         |
| Hydroxy chloroquine (n, %)       | Yes 0 (0.0%)            | 5 (100.0%)                 |         |
|                                  | 0.4a                    |                            |         |
| Sodium chloride (n, %)           | Yes 14 (12.17%)         | 101 (87.8%)                |         |
|                                  | No 0 (0.0%)             | 32 (100.0%)                |         |
| Remdesivir (n, %)                | Yes 11 (14.15%)         | 85 (88.55%)                | 0.88b   |
|                                  | No 3 (12.5%)            | 21 (87.5%)                 |         |
| Death (n, %)                     | Yes 14 (15.9%)          | 74 (84.1%)                 | 0.016b  |
|                                  | No 0 (0.0%)             | 32 (100.0%)                |         |
| Discharge in good general condition (n, %) | Yes 0 (0.0%) | 53 (100.0%) | <0.001a |
|                                  | No 14 (20.9%)           | 53 (79.1%)                 |         |

Systolic BP (Mean ± SD, mmHg)     127.29 ± 29.5 125.6 ± 20.1   0.172a
Diasstolic BP (Mean ± SD, mmHg)   79.0 ± 12.6  77.5 ± 12.8   0.684a
PR (Mean ± SD, beats per minute) 93.86 ± 23.85 95.5 ± 16.8   0.746a
O2 saturation with oxygen therapy (Mean ± SD, %) 84.36 ± 11.9 90.4 ± 7.08 0.017a
O2 saturation without oxygen therapy (Mean ± SD, %) 73.0 ± 16.7 80.88 ± 11.9 0.11a
RR (Mean ± SD, breaths per minute) 22.62 ± 5.5 21.34 ± 8.8   0.47a

CRP (Mean ± SD, μg/mL)            90.5 ± 56.7 94.5 ± 55.2 0.8a
D-dimer (Mean ± SD, μg/mL)        2100.0 ± 12581.1 2547.04 ± 2899.6 0.54a
LDH (Mean ± SD, U/L)              1363.4 ± 10156 908.05 ± 358.06 0.005a
Urea (Mean ± SD, mg/dL)           111.3 ± 96.3 76.06 ± 36.22 <0.001a
Cr (Mean ± SD, mg/dL)             2.52 ± 2.78 1.22 ± 0.7 <0.001a
WBC (Mean ± SD, million/µL)       11.78 ± 2.26 15.0 ± 23.56 0.18a
ALC (Mean ± SD, million/µL)       1608.07 ± 2058.4 1711.5 ± 3265.2 0.87a
GFR (ml/min/1.73 m²)              48.25 ± 32.5 65.5 ± 28.4 0.076a

P abnormality (n, %)              Yes 3 (14.28%) 18 (85.72%) 0.68a
PR abnormality (n, %)              Yes 0 (0.0%) 3 (100.0%) 0.52a
QRS abnormality (n, %)             Yes 6 (17.6%) 28 (82.4%) 0.199a
ST abnormality (n, %)              Yes 8 (9.3%) 78 (90.7%) 0.199a
QT abnormality (n, %)              Yes 1 (16.66%) 5 (83.34%) 0.69a

ICU: Intensive care unit, BP: Blood pressure, PR: Pulse rate, RR: Respiratory rate, CRP: C-reactive protein, LDH: Lactate dehydrogenase, Cr: Creatinine, WBC: White blood cell, ALC: Absolute lymphocytes count, GFR: Glomerular filtration rate.

a Compared between the cardiac injury and non-cardiac injury groups using Student’s t-test.

b Compared between the cardiac injury and non-cardiac injury groups using Chi-square test.
The correlation between cardiac injury in enrolled patients and different variables.

| Variables                  | TPI (µg/L, Mean ± SD) | P-value | ρ² |
|----------------------------|------------------------|---------|----|
| **Demographics**           |                        |         |    |
| Diabetes                   | Yes                    | 21.4 ± 10.4 | 0.187 | 0.121 |
|                           | No                     | 0.5 ± 2.8  |       |      |
| Hypertension               | Yes                    | 1.8 ± 9.1  | 0.2   | 0.118 |
|                           | No                     | 0.3 ± 0.65 |       |      |
| Ischemic heart disease     | Yes                    | 3.6 ± 14.9 | 0.05  | 0.176 |
|                           | No                     | 0.56 ± 2.56|       |      |
| Age                       |                        | 1.08 ± 6.54| 0.019 | 0.182 |
| Gender Male                |                        | 0.7 ± 3.3  | 0.55  | 0.23  |
|                           | Female                 | 1.3 ± 8.2  |       |      |
| Smoker                     | Yes                    | 0.17 ± 0.34| 0.427 | −0.073|
|                           | No                     | 1.23 ± 7.06|       |      |
| Hospitalisation result     | Discharge in good      | 0.07 ± 0.06| 0.004 | 0.261 |
|                           | general condition       |         |       |      |
|                           | Discharge with         | 0.12 ± 0.03|       |      |
|                           | compliance             |         |       |      |
|                           | Discharge against      | 0.09 ± 0.04|       |      |
|                           | medical advice          |         |       |      |
|                           | Death                  | 2.27 ± 9.58|       |      |
|                           |                       | ± 6.54 | 0.35 | −0.86 |
| Inpatient in ICU           | Yes                    | 1.44 ± 7.59| 0.016 | 0.219 |
|                           | No                     | 0.069 ± 0.06|       |      |
| EGG abnormality            | P abnormality          | 3.38 ± 14.54| 0.68  | 0.038 |
|                           |                         | ± 5.54 |       |      |
|                           | PR abnormality         | 1.11 ± 0.61| 0.52  | −0.058|
|                           |                         | ± 6.61 |       |      |
|                           | QRS abnormality        | 1.35 ± 7.7 | 0.48  | −0.065|
|                           |                         | ± 7.7  |       |      |
|                           | ST abnormality         | 1.16 ± 6.9 | 0.69  | −0.037|
|                           |                         | ± 6.9  |       |      |
|                           | QT abnormality         | 1.11 ± 6.7 | 0.809 | −0.022|
|                           |                         | ± 6.7  |       |      |
|                           |                       | 0.45 ± 0.79|       |      |
| Vital signs                | Systolic BP (mmHg)     | 1.08 ± 6.54| 0.33  | 0.09  |
|                           | Diastolic BP (mmHg)    | ± 0.68 |       |      |
|                           | PR (beats per minute)  | 0.087 |       |      |

Table 4 (continued)

| Variables                  | TPI (µg/L, Mean ± SD) | P-value | ρ² |
|----------------------------|------------------------|---------|----|
| **Clinical laboratory tests** |                        |         |    |
| CRP (µg/mL)                |                        | 1.08 ± 0.79| 0.172 | 0.129 |
| D-dimer (µg/mL)            |                        | ± 6.54 | 0.79 | 0.037 |
| LDH (U/L)                  |                        | 0.55 ± 0.244| 0.008 | 0.244 |
| Urea (mg/dL)               |                        | 0.033 ± 0.197| 0.008 | 0.244 |
| Cr (mg/dL)                 |                        | 0.102 ± 0.353| 0.008 | 0.244 |
| GFR (mL/min/1.73 m²)       |                        | 0.76 ± 0.002| 0.008 | 0.244 |

Note: P-value and ρ² indicate the significance level and correlation coefficient, respectively. COVID-19 [15]. Similarly, 116 (37.5%) patients had elevated TPI levels and cardiac injury among 309 hospitalised COVID-19 patients [12]. Abbasi et al. also noticed that 31.5% of 257 COVID-19 patients had a cardiac injury, and the mortality rate was 21.8% [16]. Lala et al. suggested that 18.5% of 2736 patients died during hospitalisation, and 36% had elevated TPI levels [17]. Recently, Papageorgiou and coworkers showed 66% cardiac injury and 33.1% mortality during admission in 434 COVID-19 patients [18]. Further studies reported a prevalence of cardiac injury ranging from 7% to 28% in COVID-19 patients [19–21]. Interestingly, we demonstrated that COVID-19 patients with cardiac injury had higher age and serum levels of LDH, urea, and Cr. On the contrary, they had a lower hospital stay and oxygen saturation with oxygen therapy. Surprisingly, all 14 patients with cardiac injury were inpatients in ICU and died. Patients with cardiac injury had higher mortality than those without cardiac injury (100% vs 38.7%). Additionally, the prevalence of cardiac injury was significantly correlated with age, history of ischaemic heart disease, hospitalisation result, inpatient in ICU, and serum levels of urea and Cr. In line with our results, Li et al. suggested that patients with cardiac injury were mainly male and had higher age, more comorbidities such as hypertension, diabetes, cardiovascular diseases, higher hospitalisation time, higher serum WBC, D-dimer, Cr, Interleukin-6, and hs-CRP levels [13]. Shi and coworkers also reported that 19.7% of 416 patients with COVID-19 had a cardiac injury. Noteworthy, patients with cardiac injury were older, had more comorbidities such as hypertension, diabetes, coronary heart disease, and chronic heart failure, higher levels of CRP, TPI, N-terminal pro-B-type natriuretic peptide, and Cr, and had higher mortality than those without cardiac injury (51.2% vs 45.5%) [22,23]. Sundar et al. also supported that patients with elevated TPI levels were older, had more comorbidities such as ischaemic heart disease, heart failure, chronic kidney disease, higher white cell count, and consequently had higher in-hospital mortality (53.2% vs 19.0%) and death following readmission (3.2% vs 0.0%) than non-elevated TPI patients [24]. Lyu and coworkers showed that patients with cardiac injury had higher age, history of heart failure, blood urea nitrogen (BUN) and Cr levels, and higher in-hospital mortality than the no cardiac injury group [25]. Similarly, patients with positive TPI were older, had higher comorbidities, higher levels of WBC, Cr, D-dimer, NT-proBNP, need to mechanical ventilation, and death during admission (41.9% vs 16.4%) compared to patients with negative TPI [18]. Additionally, our results revealed that in-hospital dead patients had lower oxygen saturation with and without oxygen therapy than discharged patients. In contrast, D-dimer, LDH, urea, and Cr levels were significantly higher in in-hospital dead patients than in discharged patients.
patients. Consistently, previous studies noticed that non-survivors had higher levels of D-dimer, BUN, Cr, TPI, and interleukin-6 compared to the survivors [15,16]. In addition, Ayad and coworkers reported that the levels of TPI, D-dimer, CRP, and WBCs were remarkably higher in COVID-19 patients who died during hospitalisation than survivors [25]. Similarly, lung disease, age, TPI positivity, and continuous positive airway pressure ventilation were meaningfully associated with in-hospital mortality in COVID-19 patients [24].

It has been emphasised that an elevated TPI level is indicated as cardiac myocardial injury. Our results showed that in-hospital death patients had higher levels of TPI (2.27 ± 9.58 μg/L) than discharged patients (0.07 ± 0.06 μg/L). Similarly, the mean TPI level was markedly greater in non-survival patients [16.6 μg/L (10.1–40.8)] than in survival patients [3.5 μg/L (1.8–4.1)] with COVID-19 (P < 0.001) [15]. Salvatrica et al. also endorse that the TPI level was notably elevated in dead patients [36.1 (16.5–94.9)] than in discharged patients [6.3 (2.6–13.9)] with COVID-19 (P < 0.001) [27]. Additionally, plenty pieces of evidence support that a stimulated TPI level is associated with severe illness and higher mortality in COVID-19 patients [28–30]. Lu and coworkers also noticed that non-recovery COVID-19 patients with higher TPI, BNP, D-dimer, CRP, and lower lymphocyte count compared to recovery patients [31].

These results highlighted the hypothesis that initial measurement of TPI, as a myocardial injury biomarker, for patients with severe COVID-19 after hospitalisation, followed by continuous monitoring during the hospital stay, could be beneficial for early diagnosis of cardiac injury and preventing high mortality rate.

We observed 16.6% P abnormality, 2.5% PR abnormality, 34.62% QRS abnormality, 9.33 ST abnormality, and 4.8% QT abnormality in the electrocardiogram of the patients with COVID-19. In addition, we found no significant statistical differences between the prevalence of cardiac arrhythmia in cardiac injury and no-cardiac injury groups. In line with our results, Lyu et al. mentioned that COVID-19 patients had 20.5% sinus tachycardia, 4.5% sinus bradycardia, 9.1% new onset of atrial fibrillation or atrial flutter, 5.3% supraventricular tachycardia, and 2.3% ventricular tachycardia or ventricular fibrillation. However, there were also no significant statistical differences between the two cardiac and no-cardiac injury groups [25]. Another study reported that 6.9% and 0.7% of COVID-19 patients experienced AF episodes and ventricular tachycardia, respectively. They also found no significant differences between positive and negative TPI groups [18]. These studies may confirm our results regarding no difference in the prevalence of cardiac arrhythmia in patients with and without cardiac injury.

5. Limitations

Our study has some limitations. First, this study was conducted in a single centre with small sample size. Second, the analysed laboratory parameters, including TPI, were only examined at admission, whereas the dynamic changes in these indexes were not observed. Third, as shown in Table 1, our patients did not consume alcohol by self-expression. In this regard, further investigation is required to evaluate the possible confounding effects of alcohol consumption on the cardiac troponin-I level and its correlation with cardiac injuries. Therefore, further studies with a larger sample size are necessary to confirm our results.

6. Conclusion

In summary, the prevalence of cardiac damage was 11.7%, and the mortality of severe COVID-19 was 45.8%. Patients with cardiac injury had higher mortality than those without cardiac injury. Furthermore, the cardiac injury was meaningfully correlated with age, history of ischemic heart disease, hospitalisation result and mortality, inpatient in ICU, and serum levels of urea and Cr. Additionally, the discharge result significantly correlated with oxygen saturation with and without oxygen therapy and D-dimer, LDH, urea, and Cr levels. However, further studies with a larger sample size are necessary to verify our results.

### Table 5

| Characteristics (Mean ± SD) | Discharge in good general condition | Discharge with compliance | Death | Discharge against medical advice | P-value | r² |
|-----------------------------|-----------------------------------|---------------------------|-------|---------------------------------|---------|---|
| **Medications** | | | | | | |
| Famotidine (n, %) | 12 | 0 | 13 | 4 | 0.45 | 0.07² |
| Hydroxy chloroquine (n, %) | 5 | 0 | 0 | 0 | 0.014 | −0.22² |
| Remdesivir (n, %) | 43 | 1 | 44 | 8 | 0.90 | −0.01³ |
| **Vital signs** | | | | | | |
| Systolic BP (mmHg) | 125.6 ± 20.4 | 122.5 ± 10.6 | 127.5 ± 23.4 | 132.0 ± 20.44 | 0.44 | 0.07 |
| Diastolic BP (mmHg) | 78.8 ± 13.15 | 73.5 ± 19.09 | 75.5 ± 12.39 | 84.3 ± 10.02 | 0.78 | −0.026 |
| PR (beats per minute) | 93.9 ± 16.65 | 85.0 ± 19.79 | 95.2 ± 18.37 | 104.5 ± 17.49 | 0.23 | 0.11 |
| O2 saturation with oxygen-therapy (%) | 92.0 ± 5.25 | 92.5 ± 3.53 | 87.1 ± 9.7 | 91.1 ± 5.05 | 0.02 | −0.23 |
| O2 saturation without oxygen-therapy (%) | 84.4 ± 9.33 | 83.0 ± 2.82 | 76.6 ± 14.94 | 73.7 ± 21.1 | 0.001 | −0.30 |
| Temperature (°C) | 37.4 ± 0.74 | 37.3 ± 0.21 | 37.6 ± 0.84 | 37.7 ± 0.85 | 0.18 | 0.12 |
| RR (breaths per minute) | 20.9 ± 11.39 | 22.0 ± 5.65 | 22.1 ± 5.39 | 20.1 ± 4.04 | 0.71 | 0.03 |
| **Clinical laboratory tests** | | | | | | |
| CRP (μg/mL) | 90.84 ± 57.9 | 110.9 ± 79.9 | 96.1 ± 53.9 | 97.26 ± 49.3 | 0.61 | 0.05 |
| D-dimer (μg/mL) | 1337.9 ± 1237.6 | – | 3408.7 ± 3432.2 | 3023.7 ± 2705.5 | 0.019 | 0.328 |
| LDH (U/L) | 775.6 ± 270.7 | 1206.0 ± 512.6 | 1096.4 ± 606.8 | 1072.3 ± 339.8 | 0.003 | 0.308 |
| Urea (mg/dL) | 47.33 ± 32.3 | 94.6 ± 76.36 | 79.4 ± 60.1 | 41.9 ± 13.6 | 0.03 | 0.2 |
| Cr (mg/dL) | 1.08 ± 0.54 | 1.25 ± 0.07 | 1.72 ± 1.64 | 1.0 ± 1.36 | 0.06 | 0.17 |
| WBC (million/μL) | 10.66 ± 6.5 | 7.0 ± 3.25 | 19.2 ± 31.5 | 12.0 ± 7.34 | 0.12 | 0.14 |
| ALC (million/μL) | 1593 ± 2517 | 1389 ± 402 | 1890.8 ± 3926 | 1288.7 ± 1192 | 0.84 | 0.02 |

BP: Blood pressure, PR: Pulse rate, RR: Respiratory rate, CRP: C-reactive protein, LDH: Lactate dehydrogenase, WBC: White blood cell, ALC: Absolute lymphocytes count.

¹ Pearson correlation.
² Spearman correlation.
Ethical statements

This study was ethically approved by the ethics committee of Mashhad University of Medical Sciences (approval code. IR.MUMS. MEDICAL.REC.1399.579). Furthermore, written informed consent was obtained and signed by all participants.

Data availability

The data used to support the findings of this study are available from the corresponding authors upon reasonable request.

Funding

This study was financially supported by grant Number: 990339 from Mashhad University of Medical Sciences.

Authors’ contributions

Reza Javidi Dasht Bayaz: Investigation, Data Curation; Vahid Reza Askari: Formal Analysis, Writing – Original Draft, Writing – review & editing; Mohammad Teyyebi: Conceptualisation, Methodology, Investigation; Mostafa Ahmadí: Conceptualisation, Methodology; Alireza Heidari-Bakavoli: Conceptualisation, Methodology, Funding Acquisition, Investigation; Vafa Baradaran Rahimi: Formal Analysis, Writing – Original Draft, Writing – review & editing.

Consent to participate

All participants received and signed written informed consent before their inclusion in the study.

Consent for publication

All the authors gave consent for the publication of this study in the journal.

Authorship statement

All authors meet the ICMJE authorship criteria.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgments

This study was financially supported by the research council of Mashhad University of Medical Sciences (Grant Number: 990339).

References

[1] Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: a review. Radiology 2021;272(2):682–7.
[2] Ochani R, Asad A, Yassin F, Shibli S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infecc Med 2021;29(1):20–35.
[3] Dastani M, Rahimi HR, Askari VR, Jaafari MR, Jarahi L, Yaldrashi A, et al. Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: evidence of a randomized, double-blinded, placebo-controlled clinical trial. Biosfactors 2022. https://doi.org/10.1002/bios.1874. In press.
[4] Doyle MF. Central nervous system outcomes of COVID-19. Transl Res 2022;241:41–51.
[5] Gosangi B, Rubinowitz AN, Irugu D, Gange C, Bader A, Cortopassi I. COVID-19 ARDS: a review of imaging features and overview of mechanical ventilation and its complications. Emerg Radiol 2022;29(1):123–34.
[6] Sandowal Y, Jamzuki Jf Jr, Jaffe AS. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. J Am Coll Cardiol 2020;76(10):1244–58.
[7] Lomon W, Vee MP, Heidel E, Shorman MA. Elevated troponin level as a predictor of inpatient mortality in patients with infective endocarditis in the Southeast United States. BMC Infect Dis 2020;20(1):24.
[8] Wang D, Ho B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China. JAMA 2020;323(11):1061–9.
[9] Ho JS, Sia CH, Chan MY, Lin W, Wong RC. Coronavirus-induced myocarditis: a meta-summary of cases. Heart Lung 2020;49(6):681–5.
[10] Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: a systematic review and meta-analysis. PLoS One 2021;16(5):e0250602.
[11] Gnan Wj, Niy Z, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Cardiac troponin in hospitalized COVID-19 patients. Am J Cardiol 2020;155:150–3.
[12] Li J, Zhang Y, Wang F, Liu B, Li H, Tang G, et al. Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19). BMC Cardiovasc Disord 2020;20(1):479.
[13] Lu JY, Bucek A, Fleysher R, Hoogenboom WS, Hou W, Rodriguez CJ, et al. Outcomes of hospitalized patients with COVID-19 with acute kidney injury and acute cardiac injury. Front Cardiovasc Med 2021;8:798987.
[14] Fan H, Zhang L, Huang B, Zhu M, Zhou Y, Zhang H, et al. Cardiac injuries in patients with coronavirus disease 2019: not to be ignored. In: International journal of infectious diseases ; IJID. vol. 96. official publication of the International Society for Infectious Diseases; 2020. p. 294–7.
[15] Al Abbasi B, Torres P, Ramos-Tuarez F, Dawaswala N, Abdallah A, Chen K, et al. Cardiac troponin-I and COVID-19: a prognostic value for in-hospital mortality. Cardiology research 2020;11(6):398–404.
[16] Lala A, Johnson KW, Jamzuki JL, Rassajk AJ, Paranjpe I, Richter F, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol 2020;76(5):533–46.
[17] Papageorgiou N, Sohrabi C, Prieto Merino D, Tyrlis A, Atieh AE, Saberwal B, et al. High sensitivity troponin and COVID-19 outcomes. Acta Cardiol 2022;77(1):81–8.
[18] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5(7):811–8.
[19] Nie SF, Yu M, Xie T, Yang F, Wang HB, Wang ZH, et al. Cardiac troponin I is an independent predictor for mortality in hospitalized patients with COVID-19. Circulation 2020;142(6):608–10.
[20] Stefanini GI, Chiarito M, Ferretta F, Cannata F, Azzolini M, Giuggini G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart 2020;106(19):1512–8.
[21] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in wuhan, China. JAMA Cardiol 2020;5(7):802–10.
[22] Gholizadeh A, Askari VR, Naghadehi H, Ahmadii M, Vakili B, Baradaran Rahimi V. Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomized, double-blind, placebo-controlled clinical trial. Inflammmopharmacology 2021;29(3):1379–87.
[23] Shyam-Sundar V, Stein DF, Spazzapan M, Sullivan A, Qin C, Voon V. Troponin and short-term mortality in hospitalized patients with COVID-19 infection: a retrospective study in an inner-city London hospital. BMJ Open 2022;12(8):e064426.
[24] Lu Y, Chouhday K, Miskovski J, Armenio V, Wu WC. Causes of death in COVID-19 patients with cardiac injury. J Med J 2020;13(5):25–32. 2022.
[25] Ali AM, Rostom HM, Fatah MI, Noor CM, Ali KM, Tasrifqe HM. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immune Inflam Med 2022;10(3):e052.
[26] Salvatici M, Barbieri B, Cioffi SMG, Morengi E, Leone FP, Maura F, et al. Association between cardiac troponin I and mortality in patients with COVID-19. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2020;25(8):634–40.
[27] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):507–13.
[28] Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63(3):364–74.
[29] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(5):846–8.
[30] Lu JQ, Lu JY, Wang W, Liu Y, Bucek A, Fleysher R, et al. Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19. ElBioMedicine 2022;76:103821.